ClinicalTrials.gg

Program

Oligonucleotides, Antisense

Also written as “NIO752” and “antisense oligonucleotide”.

In Novartis's pipeline, Tau antisense oligonucleotide. Its studies are mostly in Supranuclear Palsy, Progressive · Alzheimer Disease, led by Novartis.

Furthest: phase 2, since Oct 5, 20263 company-led studies, 2 open or runningNext primary completion: Mar 26, 2029 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Novartis32 open or runningphase 2since Oct 5, 2026Aug 25, 2020Mar 26, 2029phase 2 · NCT07868328
  • Named in Novartis’s own pipeline as NIO752, phase 3, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Aug 25, 2020First study: phase 1 study in Supranuclear Palsy, ProgressiveFirst studyNCT04539041 · 59 enrolled · United States, Canada, Germany and more
  2. Jul 11, 2022Phase 1 study in Alzheimer DiseaseNCT05469360 · 38 enrolled · Finland, France, Spain and more
  3. Oct 5, 2026Phase 2 study in Supranuclear Palsy, ProgressivePhase 2 reachedNCT07868328 · 48 planned

Ahead

  1. Mar 26, 2029Primary completion: phase 2 study in Supranuclear Palsy, ProgressiveNCT07868328

TargetBeta

“Tau antisense oligonucleotide”the company's pipeline, read by Claude · source

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07868328Supranuclear Palsy, Progressive2Not yet recruitingMar 26, 202948
NCT05469360Alzheimer Disease · Finland, France, Spain and more1Active, not recruitingJul 30, 202638
NCT04539041Supranuclear Palsy, Progressive · United States, Canada, Germany and more1CompletedOct 17, 202459

How it is read

Names in the registry

  • “NIO752”, 6 entries
  • “antisense oligonucleotide”, 1 entry

Codes read as this program: NIO752.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.